David M. Brizel
Department of Radiation Oncology
Duke University
Durham
USA
Name/email consistency: high
- Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Brizel, D.M., Murphy, B.A., Rosenthal, D.I., Pandya, K.J., Glück, S., Brizel, H.E., Meredith, R.F., Berger, D., Chen, M.G., Mendenhall, W. J. Clin. Oncol. (2008)
- Pharmacologic approaches to radiation protection. Brizel, D.M. J. Clin. Oncol. (2007)
- Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Brizel, D.M., Prosnitz, R.G., Hunter, S., Fisher, S.R., Clough, R.L., Downey, M.A., Scher, R.L. Int. J. Radiat. Oncol. Biol. Phys. (2004)
- Does amifostine have a role in chemoradiation treatment?. Brizel, D.M., Overgaard, J. Lancet Oncol. (2003)
- Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Brizel, D.M., Schroeder, T., Scher, R.L., Walenta, S., Clough, R.W., Dewhirst, M.W., Mueller-Klieser, W. Int. J. Radiat. Oncol. Biol. Phys. (2001)
- Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Brizel, D.M., Wasserman, T.H., Henke, M., Strnad, V., Rudat, V., Monnier, A., Eschwege, F., Zhang, J., Russell, L., Oster, W., Sauer, R. J. Clin. Oncol. (2000)
- Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Brizel, D.M., Sibley, G.S., Prosnitz, L.R., Scher, R.L., Dewhirst, M.W. Int. J. Radiat. Oncol. Biol. Phys. (1997)
- Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Brizel, D.M., Scully, S.P., Harrelson, J.M., Layfield, L.J., Bean, J.M., Prosnitz, L.R., Dewhirst, M.W. Cancer Res. (1996)









